sub:assertion {
  d:DB00313 v:identifier "DB00313" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB00313" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB00313> ;
    dv:drugbank-id "APRD00066" , "APRD00256" , "DB00313" , "DB00510" ;
    dv:x-ahfs <http://bio2rdf.org/ahfs:28:12.92> ;
    dv:x-atc <http://bio2rdf.org/atc:N03AG01> ;
    dv:x-cas <http://bio2rdf.org/cas:99-66-1> ;
    dv:x-chebi <http://bio2rdf.org/chebi:9926> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:3009> ;
    dv:x-dpd <http://bio2rdf.org/dpd:2260654> ;
    dv:x-kegg <http://bio2rdf.org/kegg:C07185> , <http://bio2rdf.org/kegg:D00399> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0121-0675-16> ;
    dv:x-pharmgkb <http://bio2rdf.org/pharmgkb:PA451846> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:3121> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:46505925> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Valproic_Acid> ;
    dct:description "Valproic acid, supplied as the sodium salt valproate semisodium or divalproex sodium, is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (CAS number: 76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers."@en ;
    dct:identifier "drugbank:DB00313" ;
    dct:title "Valproic Acid"@en ;
    a dv:Drug ;
    rdfs:label "Valproic Acid [drugbank:DB00313]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB00313> , <http://www.drugs.com/cdi/valproate.html> , <http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dep1124.shtml> , <http://www.rxlist.com/cgi/generic2/depakene.htm> .
}